Alpha Teknova downgraded by BTIG Research
$TKNO
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
BTIG Research downgraded Alpha Teknova from Buy to Neutral
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/10/2025 | $12.00 | Buy | Craig Hallum |
| 3/12/2024 | Buy → Neutral | BTIG Research | |
| 7/20/2021 | Overweight | Stephens | |
| 7/20/2021 | $27.00 | Overweight | Stephens & Co. |
| 7/20/2021 | Outperform | Cowen & Co. | |
| 7/20/2021 | $26.00 | Buy | BTIG |
S-8 - Alpha Teknova, Inc. (0001850902) (Filer)
10-K - Alpha Teknova, Inc. (0001850902) (Filer)
8-K - Alpha Teknova, Inc. (0001850902) (Filer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
HOLLISTER, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the research, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the appointment of Martha J. Demski to its Board of Directors, bringing to the Board more than 35 years of experience in corporate leadership and life sciences business and financial strategies. She will replace Robert McNamara, who has served on the Board since Teknova's IPO in 2021 and has announced his intention to step down to pursue other opportunities. Both Ms. Demski's appointment and Mr. McNamara's resignation will be ef
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to partic
HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innovative technologies designed to shorten the development lifecycle of tomorrow's cell therapies. As previously announced, Teknova and Plu
HOLLISTER, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), and Pluristyx, Inc., today announced that the companies are collaborating to produce and commercialize Pluristyx's PluriFreeze™ product line, a cryopreservative and cell wash media system intended for use by customers who are developing next generation allogeneic cell therapies. Teknova is a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, while Pluristyx is a leading provider of induced Pluripotent Stem Cells (iPSCs), including immune evading and safety-switch enabled iPSCs, and other innova
Craig Hallum initiated coverage of Alpha Teknova with a rating of Buy and set a new price target of $12.00
BTIG Research downgraded Alpha Teknova from Buy to Neutral
Stephens initiated coverage of Alpha Teknova with a rating of Overweight
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
4 - Alpha Teknova, Inc. (0001850902) (Issuer)
SC 13D - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)
SC 13G/A - Alpha Teknova, Inc. (0001850902) (Subject)
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market. Teknova will host a webcast and conference call on Thursday, May 8, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you would like to partic
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidanceFourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior yearCompany provides 2025 revenue guidance of $39-42 million HOLLISTER, Calif., March 04, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova" or the "Company") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the fourth quarter and full year ended December 31, 2024. "I am very proud of our execution in 2024, across-the-board," said Stephen Gunstream, Pre
HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. ("Teknova") (NASDAQ:TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market. Teknova will host a webcast and conference call on Tuesday, March 4, 2025, beginning at 5 p.m. Eastern Time. To access the live webcast, listeners can log onto the call from the Investor Relations section of the Teknova website or by using this link. If you w